Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DW1OK0
|
|||
| Drug Name |
BIIB111
|
|||
| Drug Type |
Gene therapy
|
|||
| Indication | Choroideremia [ICD-11: 9B61] | Phase 3 | [1] | |
| Company |
Biogen
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Rab proteins geranylgeranyltransferase component A 1 (CHM) | Target Info | . | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03496012) A Randomised, Open Label, Outcomes-Assessor Masked, Prospective, Parallel Controlled Group, Phase 3 Clinical Trial of Retinal Gene Therapy for Choroideremia Using an Adeno-Associated Viral Vector (AAV2) Encoding Rab Escort Protein 1 (REP1). U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.